Drugs / BGM0504 tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07658560 | Jun 2026 → Feb 2027 expected | — | BrightGene Bio-Medical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGM0504 tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07658560 ↗ |
| Route | Oral | “Administered p.o once daily” NCT07658560 ↗ |